Multiple paths to a drug resistance phenotype: mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs.

Abstract excerpt

The remarkable responses observed with imatinib (Gleevec) in the therapy of CML led many scientists to think that drug resistance, long recognized as a problem with "cytotoxic" agents, would soon become a thing of the past. But then reality set in. We learned that imatinib, a wonderful drug by any measure, was also susceptible to the development of resistance, as was gefitinib (Iressa), and then erlotinib...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antineoplastic Agents
• Share to Drug Resistance, Neoplasm